GlassScriptPhysician profile
Meng Huy Luy
NPI 1396506598
$5,594.81
in general payments reported to CMS, 2019-2025
23 companies · $2,892 in 2025
The $2,892 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,703 · 2025: $2,892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,405 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,404.82 |
| Education | $189.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,595.41 | 2024-2025 | |
| Amgen INC. | $1,046.13 | 2024-2025 | Evenity, Otezla, Enbrel |
| Janssen Biotech, INC. | $627.18 | 2024-2025 | Tremfya |
| Ucb, INC. | $491.73 | 2024-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $468.14 | 2024-2025 | |
| Radius Health, INC. | $304.11 | 2024-2025 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $172.80 | 2024-2025 | Orencia |
| Astrazeneca Pharmaceuticals LP | $171.42 | 2024-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $167.76 | 2024-2025 | Benlysta |
| Ani Pharmaceuticals, INC. | $134.27 | 2024-2025 | Purified Cortrophin Gel, Sovuna |
| Lilly USA, LLC | $73.89 | 2024 | Taltz |
| Alexion Pharmaceuticals, INC. | $64.40 | 2024 | Strensiq |
| Azurity Pharmaceuticals, INC. | $48.05 | 2024 | Horizant |
| Vertex Pharmaceuticals Incorporated | $31.75 | 2025 | |
| Invivyd INC | $29.18 | 2025 | Pemgarda |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shorla Oncology INC. | $28.41 | 2024 | |
| Almatica Pharma LLC | $24.92 | 2025 | Teriparatide |
| Tonix Medicines, INC. | $24.04 | 2025 | Tonmya |
| Organon LLC | $22.52 | 2025 | |
| Aurinia Pharma U.S., INC. | $22.50 | 2024 | Lupkynis |
| Fidia Pharma USA INC. | $18.88 | 2025 | Hymovis |
| Genentech USA, INC. | $14.25 | 2024 | Actemra |
| Scilex Pharmaceuticals INC. | $13.07 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meng Luy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.